Prospective assessment of two-stage testing for Clostridium difficile

The Journal of Hospital Infection
A ArnoldTim Planche

Abstract

Commonly used immunoassays have limitations as stand-alone tests for the diagnosis of Clostridium difficile infection (CDI). In particular, the specificity of these assays means that these tests generate a relatively large number of false-positive results. We introduced a two-stage regimen for CDI as routine. Unformed stool samples received in our laboratory were initially tested with a Meridian Premier enzyme immunoassay (EIA) and positive samples were retested with reference testing methods (toxigenic culture and cell cytotoxicity assay). Clinicians received diagnostically useful information on the day that the sample arrived in the laboratory, with definitive negative and provisional positive results made available. We reviewed the first 3643 unformed stool specimens of which 158/3643 (4.3%) were provisionally positive by EIA. Of the 158 samples that were EIA positive, 119 were confirmed as being positive by at least one of the reference methods, giving a positive predictive value in this population of 75% (95% confidence interval: 67.6-81.7%). Comparison of the optical density values of the EIA lying between true and false-positive results suggests that the introduction of a second cut-off value would improve diagnostics. A...Continue Reading

References

Feb 1, 1979·Journal of Clinical Microbiology·W L GeorgeS M Finegold
Jul 1, 1987·Journal of Clinical Microbiology·M T KellyJ A Smith
Apr 12, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H VanpouckeG Verschraegen
Feb 1, 2002·The New England Journal of Medicine·John G Bartlett
Jul 9, 2004·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Susan M Poutanen, Andrew E Simor
Feb 7, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John G Bartlett, Dale N Gerding
Nov 4, 2008·The Lancet Infectious Diseases·Tim PlancheSanjeev Krishna
Feb 27, 2009·Journal of Clinical Microbiology·Frédéric BarbutCatherine Eckert

❮ Previous
Next ❯

Citations

Jul 5, 2013·Clinical Microbiology Reviews·Carey-Ann D Burnham, Karen C Carroll
Jan 11, 2011·The Journal of Hospital Infection·S D GoldenbergG L French
Nov 26, 2010·Current Opinion in Gastroenterology·Caoilfhionn O'Donoghue, Lorraine Kyne
Dec 10, 2014·Diseases of the Colon and Rectum·Scott R SteeleJanice Rafferty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2021 Meta ULC. All rights reserved